The role of nanoparticle size in hemocompatibility

Mayer, Allen; Vadon, Maria; Rinner, Beate; Novak, Alexandra; Wintersteiger, Reinhold; Frőhlich, Eleonore

doi:10.1016/j.tox.2009.01.015

Cited by 195 publications

(138 citation statements)

References 50 publications

Supporting

Mentioning

130

Contrasting

Order By: Relevance

“…The binding of GQDs to the RBC molecule can be linked to the small particle size of GQDs which is also linked to the strong electrostatic interactions with phosphatidylcholine lipids present on the surface of the RBC membrane [72]. In agreement with our findings, the size-dependent cytotoxicity on human RBCs and mammalian cells has been reported earlier testing other nanoparticles, such as silica [73,74] and latex ones [75]. In addition, studies on hemolytic activity of silver nanoparticles showed that the release of low silver ion concentrations leads to the death of RBC molecule [76].…”

Section: Hemolytic Activitysupporting

confidence: 91%

Nanofabrication of Graphene Quantum Dots with High Toxicity Against Malaria Mosquitoes, Plasmodium falciparum and MCF-7 Cancer Cells: Impact on Predation of Non-target Tadpoles, Odonate Nymphs and Mosquito Fishes

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Hemolytic Activitysupporting

confidence: 91%

Nanofabrication of Graphene Quantum Dots with High Toxicity Against Malaria Mosquitoes, Plasmodium falciparum and MCF-7 Cancer Cells: Impact on Predation of Non-target Tadpoles, Odonate Nymphs and Mosquito Fishes

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[60][61][62][63] To assess the in vivo utility of a nanoformulation as a carrier for curcumin, the hemolytic potential in human blood needs to be tested. 64,65 Therefore, we evaluated a direct nanoparticle-erythrocyte membrane interaction in which the extent of disruption of the erythrocyte membrane was a direct measure of nanoparticle toxicity (Figure 4).…”

Section: Hemolysismentioning

confidence: 99%

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Yallapu¹,

Ebeling²,

Chauhan³

et al. 2011

IJN

View full text Add to dashboard Cite

Background Recent studies report curcumin nanoformulation(s) based on polylactic- co -glycolic acid (PLGA), β-cyclodextrin, cellulose, nanogel, and dendrimers to have anticancer potential. However, no comparative data are currently available for the interaction of curcumin nanoformulations with blood proteins and erythrocytes. The objective of this study was to examine the interaction of curcumin nanoformulations with cancer cells, serum proteins, and human red blood cells, and to assess their potential application for in vivo preclinical and clinical studies. Methods The cellular uptake of curcumin nanoformulations was assessed by measuring curcumin levels in cancer cells using ultraviolet-visible spectrophotometry. Protein interaction studies were conducted using particle size analysis, zeta potential, and Western blot techniques. Curcumin nanoformulations were incubated with human red blood cells to evaluate their acute toxicity and hemocompatibility. Results Cellular uptake of curcumin nanoformulations by cancer cells demonstrated preferential uptake versus free curcumin. Particle sizes and zeta potentials of curucumin nanoformulations were varied after human serum albumin adsorption. A remarkable capacity of the dendrimer curcumin nanoformulation to bind to plasma protein was observed, while the other formulations showed minimal binding capacity. Dendrimer curcumin nanoformulations also showed higher toxicity to red blood cells compared with the other curcumin nanoformulations. Conclusion PLGA and nanogel curcumin nanoformulations appear to be very compatible with erythrocytes and have low serum protein binding characteristics, which suggests that they may be suitable for application in the treatment of malignancy. These findings advance our understanding of the characteristics of curcumin nanoformulations, a necessary component in harnessing and implementing improved in vivo effects of curcumin.

show abstract

“…The phase-transition temperature of a bilayer lipid membrane directly determines its liquidity, which in turn affects the release of CU from liposomes. Under the experimental temperature conditions, the lower film liquidity of the bilayer lipid membrane in CU-HSPC-C was less than in CU-SPC-C, which slowed down the release of CU from the CU-HSPC-C. Hemolysis is a type of acute toxicity assay used to evaluate the hemocompatibility of the complexes and to detect hemolyzation of red blood cells (Koziara et al, 2005;Ciochina et al, 2009;Mayer et al, 2009;Shelma & Sharma, 2011). To evaluate the in vivo utility of a CU-PC-C and CU-HSPC-C as a carrier for CU, the hemolytic potential in human blood needs to be tested (Fischer & Chan, 2007;Grainger, 2009).…”

Section: Discussionmentioning

confidence: 99%

Development, characterization and toxicological evaluations of phospholipids complexes of curcumin for effective drug delivery in cancer chemotherapy

et al. 2014

View full text Add to dashboard Cite

The purpose of this study was to prepare and characterize the complexes between curcumin (CU) phosphatidylcholine (PC) and hydrogenated soya phosphatidylcholine (HSPC) and to evaluate their anticancer activity. These CU-PC and CU-HSPC complexes (CU-PC-C and CU-HSPC-C) were evaluated for various physical parameters like Fourier transform infrared spectroscopy, melting point, solubility, scanning electron microscopy and the in vitro drug release study. These data confirmed the formation of phospholipids complexes. The in vitro hemolysis study showed that the complex was non-hemolytic. The anti-cancer potential of the complexes was demonstrated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay in MCF-7 cell line. This increase may be due to the amphiphilic nature of the complexes, which significantly enhances the water and lipid solubility of the CU. Unlike the free CU (which showed a total of only 90% drug release at the end of 8 h), complex showed around 40-60% release at the end of 8 h in dissolution studies. It showed that (when given in equimolar doses) complexes have significantly decreased the amount of CU available for absorption as compared with CU-free drug. Both CU-PC-C and CU-HSPC-C were found to be non-toxic at the dose equivalent to 2000 mg/kg of body weight of CU in the toxicity study. Acute and subacute toxicity studies confirmed the oral safety of the formulation. A series of genotoxicity studies was conducted, which revealed the non-genotoxicity potential of the developed complexes. Thus, it can be concluded that the phospholipid complexes of CU may be a promising candidate in cancer therapy.

show abstract

The role of nanoparticle size in hemocompatibility

Cited by 195 publications

References 50 publications

Nanofabrication of Graphene Quantum Dots with High Toxicity Against Malaria Mosquitoes, Plasmodium falciparum and MCF-7 Cancer Cells: Impact on Predation of Non-target Tadpoles, Odonate Nymphs and Mosquito Fishes

Nanofabrication of Graphene Quantum Dots with High Toxicity Against Malaria Mosquitoes, Plasmodium falciparum and MCF-7 Cancer Cells: Impact on Predation of Non-target Tadpoles, Odonate Nymphs and Mosquito Fishes

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Development, characterization and toxicological evaluations of phospholipids complexes of curcumin for effective drug delivery in cancer chemotherapy

Contact Info

Product

Resources

About